The industry urgently needs to understand that its current approach to policy is almost pre-destined to deliver disappointment and poor outcomes.
The choice is to be more defensive or continue to suffer bad outcomes
September 19, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Medicines Australia calls for Budget action to restore access to innovative medicines
February 3, 2026 - - Latest News -
Survey exposes deep gaps in support for Australians living with rare cancers
February 3, 2026 - - Latest News -
Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down
February 3, 2026 - - Latest News -
AusBiotech and Medicines Australia unite to accelerate advanced therapies
February 3, 2026 - - Latest News -
If you're going to pay for reforms, are these the changes you want to pay for?
February 3, 2026 - - Latest News -
Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy
February 2, 2026 - - Latest News -
AusBiotech urges adoption of national life sciences strategy as global competition intensifies
February 2, 2026 - - Australian Biotech

